Management of Metastatic Non-Small Cell Lung Cancer without an Actionable Mutation

1

Introduction

00:00 • 4min

2

Lung Cancer and Antibody Drug Conjugates

03:32 • 2min

3

IOs and Biomarker Assessment in Community Based Practice

05:02 • 4min

4

Do You Give Chemotherapy to Patients With High PD-1 Levels?

09:31 • 3min

5

IO-Monotherapy in Non-Small Cell Lung Cancer?

12:44 • 2min

6

Lung Cancer - Is There a Cure?

15:12 • 2min

7

CTL-4 Inhibitors in Lung Cancer Trials

17:30 • 3min

8

IPNivo Versus Thervatremi - Is There a Correlation of Toxicity and Treatment Benefit?

20:25 • 3min

9

How Many People in Your Practice Have Metastatic Non-Small Cell Lung Cancer in Five Years?

23:30 • 4min

10

Is There a KRS G12A Mutation in Melanoma?

27:16 • 3min

11

Is Gem Cytobene a Surrogate for Squamous Cell Disease?

30:03 • 3min

12

Hypothyroidism - What's the Spectrum of Thyroid Abnormalities?

33:23 • 2min

13

Is There a Higher Risk of TKI's After Immunotherapy?

35:04 • 2min

14

A Case Study on Data-Potomab-Dirac-Stikan

37:23 • 2min

15

Are You Interested in Targeting EJFR Activating Mutations?

39:36 • 2min

16

Dosage in a Frail Patient?

41:43 • 2min

17

Is There a Disparity in Oncology?

44:01 • 4min

18

Is There a Disparity Plan in Clinical Trials?

47:48 • 2min